ACE Inhibitor in the Treatment of Cutaneous and Lymphatic Sarcoidosis

  title={ACE Inhibitor in the Treatment of Cutaneous and Lymphatic Sarcoidosis},
  author={Vinod Kaura and Samantha H Kaura and Claire S Kaura},
  journal={American Journal of Clinical Dermatology},
Angiotensin-converting enzyme is used as a marker for sarcoid activity. We describe a case of remission of cutaneous and lymphatic sarcoidosis in a patient treated with an ACE inhibitor for congestive heart failure and hypertension; the remission has continued over 4 years of follow-up. Because this is a report of only one case, there is a possibility of sampling error. Whether the patient’s remission in this case was a serendipitous spontaneous remission that happened to occur during ACE… Expand
Angiotensin-converting enzyme inhibitors in the treatment of sarcoidosis and association with ACE gene polymorphism: case series.
An observational study of four African-American patients all of whom demonstrated improvement in their sarcoidosis after treatment with ACE inhibitors for hypertension is presented. Expand
Sarcoidosis and the rheumatologist
This article reviews diagnostic and treatment challenges that rheumatologists face in the diagnosis and treatment of sarcoidosis and concludes that Tumor necrosis factor inhibition therapy is a viable alternative for immunodulation for various manifestations. Expand
Interstitial granulomatous drug reaction presenting as erythroderma: remission after discontinuation of enalapril maleate
This work has shown that Plasma levels of tumor necrosis factor-alpha (TNF-alpha) are essentially dependent on visceral fat amount in type 2 diabetic patients and the importance of body mass index, waist circumference, and waist ⁄hip ratio in predicting incident diabetes. Expand
Manifestations of cutaneous sarcoidosis: a case report of an African American woman.
A case of cutaneous sarcoidosis in a patient presenting with multiple lesions is described, which involves not only clinical and pathologic findings but also multiple exclusions. Expand
Granulomatous drug eruption associated with imipramine
The first case, to the knowledge, of a granulomatous drug eruption associated with imipramine is reported, used to treat depression as well as enuresis. Expand


Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
Thalidomide, particularly because of its inhibition of the macrophage function, may be a useful alternative therapy in steroid-resistant cases and the correlation between the angiotensin-converting enzyme level and the clinical improvement observed in patients suggests a direct parallel between angiotENSin- Converting enzyme and the activity of the granulomatous process. Expand
Immunohistologic diagnosis of sarcoidosis. Detection of angiotensin-converting enzyme in sarcoid granulomas.
Angiotensin-converting enzyme (ACE) was detected by indirect immunofluorescence examination and appears to be a distinct aid in establishing a definitive tissue diagnosis of sarcoidosis. Expand
Serum Angiotensin Converting Enzyme in Sarcoidosis—Its Value in Present Clinical Practice
There continues to be considerable interest in SACE in sarcoidosis and with the recent development of simpler assays, more centres may be expected to offer SACE measurements as a service. Expand
Treatment of Cutaneous Sarcoidosis with Tranilast
Two cutaneous sarcoidosis patients were treated with tranilast, resulting in remission within three months of administration, and this drug should be an excellent tool for the treatment of other granulomatous diseases. Expand
Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas.
To avoid the use of systemic corticosteroids, 17 patients with cutaneous sarcoidal granulomas with hydroxychloroquine were treated with 2 to 3 mg/kg/day in an open clinical trial and two of eight patients with pulmonary sarcoidosis improved. Expand
Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis.
Serum ACE was significantly reduced in patients with chronic obstructive lung disease, lung cancer, tuberculosis and cystic fibrosis, as compared to control subjects, and was even lower in those receiving corticosteroids. Expand
Weekly low-dose methotrexate therapy for cutaneous sarcoidosis.
Three patients with severe, treatment-resistant cutaneous sarcoidosis were treated with low-dose oral methotrexate on a weekly basis. Facial granulomas and ulcerations responded best. A response wasExpand
Corticosteroid therapy in pulmonary sarcoidosis: a systematic review.
Oral corticosteroids improved results on the chest radiograph following 6 to 24 months of treatment and produced a small improvement in vital capacity and diffusing capacity, and there were no data to suggest that cortiosteroid therapy alters long-term disease progression. Expand
A case of cutaneous acral sarcoidosis with response to allopurinol
Interestingly, in Cushing's disease, skin signs such as striae, atrophy, and bruising may be much less marked, than in iatrogenic Cushing’s syndrome and hence may lead to a delay in the diagnosis, so it is less likely that the patient's PG was associated with underlying diabetes mellitus. Expand
Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.
Thalidomide is a useful addition to the therapeutic armamentarium for treatment-resistant dermatoses as long as proper vigilance for adverse effects is maintained. Expand